A purified antibody or hyperimmune that is specific for the hepatitis B virus - HepaGam B™ is Cangene's Hepatitis B Immune Globulin Intravenous (Human) which was approved by the USFDA last year for the treatment of exposure to blood containing HBsAg (hepatitis B surface antigen): perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute hepatitis B virus infection.
Also, HepaGam B™ and was approved earlier this year by Health Canada for prevention of Hepatitis B recurrence following liver transplantation in adult patients.
Now, the USFDA has approved HepaGam B™ for the prevention of hepatitis B recurrence following liver transplantation in hepatitis B surface antigen ("HBsAg")-positive liver transplant patients.
According to Dr. John Langstaff, president and chief executive officer of Cangene (TSE: CNJ):
"This is a very important approval and addresses a significant medical need. And with the recent agreement for distribution of this product with Novation, the timing could not be better.”
Find more details from the full report.
.jpg)
Comment Preview